The KEYNOTE-012 (NCT01848834) phase I trial (n = 39) investigated the efficacy of pembrolizumab in patients with advanced solid tumors, including recurrent or metastatic PD-L1 positive gastric cancer (~40% of all gastric cancers). Here, CD274 is linked to gastric cancer.